Williams P, Qazi S, Agarwal R, Velaphi S, Bielicki J, Nambiar S, et al. Antibiotics needed to treat multidrug-resistant infections in neonates. Bull World Health Organ. 2022;100(12):797–807.

Article  PubMed  PubMed Central  Google Scholar 

Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106(8):745–52.

Article  PubMed  Google Scholar 

Sivanandan S, Jain K, Plakkal N, Bahl M, Sahoo T, Mukherjee S, et al. Issues, challenges, and the way forward in conducting clinical trials among neonates: investigators’ perspective. J Perinatol. 2019;39(S1):20–30.

Article  PubMed  PubMed Central  Google Scholar 

Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787–98.

Article  CAS  PubMed  Google Scholar 

Chung E, Sen J, Patel P, Seto W. Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review. Clin Pharmacokinet. 2021;60(8):985–1001.

Article  CAS  PubMed  Google Scholar 

Lee SM, Yang S, Kang S, Chang MJ. Population pharmacokinetics and dose optimization of vancomycin in neonates. Sci Rep. 2021. https://doi.org/10.1038/s41598-021-85529-3.

Article  PubMed  PubMed Central  Google Scholar 

Marta MT, Marta AM, Laura HH, Victoria GNM. Target attainment and clinical efficacy for vancomycin in neonates: systematic review. Antibiotics (Basel). 2021;10(4):347.

Article  Google Scholar 

Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.

Article  CAS  PubMed  Google Scholar 

Puig M. Body composition and growth. In: Walker WA, Watkins JB, editors. Nutrition in Pediatrics, 2nd edn. Hamilton, Ontario, BC Decker; 1996.

Allegaert K, Mian P, van den Anker JN. Developmental pharmacokinetics in neonates: maturational changes and beyond. Curr Pharm Des. 2018;23(38):5769–78.

Article  Google Scholar 

Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004;38(10):1702–6.

Article  PubMed  Google Scholar 

Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 2006;14(12):993–1003.

Article  PubMed  Google Scholar 

Taylor ZL, Poweleit EA, Paice K, Somers KM, Pavia K, Vinks AA, et al. Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing. CPT Pharmacometrics Syst Pharmacol. 2023;12(12):1827–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu YX, Wen H, Niu WJ, Li JJ, Li ZL, Jiao Z. External evaluation of vancomycin population pharmacokinetic models at two clinical centers. Front Pharmacol. 2021;12: 623907.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, et al. Predictive performance of a vancomycin population pharmacokinetic model in neonates. Infect Dis Ther. 2015;4(2):187–98.

Article  PubMed  PubMed Central  Google Scholar 

Crcek M, Zdovc J, Kerec KM. A review of population pharmacokinetic models of gentamicin in paediatric patients. J Clin Pharm Ther. 2019;44(5):659–74.

Article  CAS  PubMed  Google Scholar 

Illamola SM, Sherwin CM, van Hasselt JGC. Clinical pharmacokinetics of amikacin in pediatric patients: a comprehensive review of population pharmacokinetic analyses. Clin Pharmacokinet. 2018;57(10):1217–28.

Article  CAS  PubMed  Google Scholar 

Engle W. Age terminology during the perinatal period. Pediatrics. 2004;114(5):1362–4.

Article  PubMed  Google Scholar 

Cristea S, Allegaert K, Falcao AC, Falcao F, Silva R, Smits A, et al. Larger dose reductions of vancomycin required in neonates with patent ductus arteriosus receiving indomethacin versus ibuprofen. Antimicrob Agents Chemother. 2019;63(8):e00853-e919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jarugula P, Akcan-Arikan A, Munoz-Rivas F, Moffett BS, Ivaturi V, Rios D. Optimizing vancomycin dosing and monitoring in neonates and infants using population pharmacokinetic modeling. Antimicrob Agents Chemother. 2022. https://doi.org/10.1128/aac.01899-21.

Article  PubMed  PubMed Central  Google Scholar 

Seay RE, Brundage RC, Jensen PD, Schilling CG, Edgren BE. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol Ther. 1994;56(2):169–75.

Article  CAS  PubMed  Google Scholar 

Burstein AH, Gal P, Forrest A, Bcps P, Pharmd AF. Evaluation of a sparse sampling strategy for determining vancomycin pharmacokinetics in preterm neonates: application of optimal sampling theory. Ann Pharmacother. 1997;31(9):980–3.

Article  CAS  PubMed  Google Scholar 

Capparelli EV, Lane FR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. Clin Pharmacol. 2001;41(9):927–34.

Article  CAS  Google Scholar 

Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, et al. Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J Clin Pharmacol. 2014;78(5):1090–101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelman A. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol. 1984;18(5):685–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thomson A, Wayb S, Bryson S, McGovern E, Kelman A, Whitinga B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther. 1988;11(3):173–9.

Article  CAS  PubMed  Google Scholar 

Izquierdo M, Lanao JM, Cervero L, Jimenez NV, Domínguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit. 1992;14(3):177–83.

Article  CAS  PubMed  Google Scholar 

Touw D, Proost J, Stevens R, Lafeber H, van Weissenbruch M. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. Pharm World Sci. 2001;23(5):200–4.

Article  CAS  PubMed  Google Scholar 

De Cock RFW, Allegaert K, Schreuder MF, Sherwin CMT, De Hoog M, Van Den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105–17.

Article  PubMed  Google Scholar 

Illamola SM, Colom H, van Hasselt JGC. Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies. Br J Clin Pharmacol. 2016;82(3):793–805.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matcha S, Dillibatcha J, Raju AP, Chaudhari BB, Moorkoth S, Lewis LE, et al. Predictive performance of population pharmacokinetic models for amikacin in term neonates. Pediatr Drugs. 2023;25(3):365–75.

Article  Google Scholar 

Smits A, De Cock RFW, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CAJ. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–51.

Article  CAS  PubMed  PubMed Central